What are the target audiences for Voranigo, the Lusius version of Laos? Restrictions?
Voranigo is suitable for patients with specific gene mutations, but there are strict restrictions such as pregnancy ban and dosage adjustment for liver function abnormalities. The risks and benefits of use need to be evaluated based on individual circumstances.
1. Applicable population
(1) Gene mutation patients: Solid tumor patients confirmed to have NTRK gene fusion through testing, suitable for adults and children aged ≥ 12 years.
(2) Recurrent/refractory tumors: Patients with advanced or metastatic tumors who have failed standard treatment.
(3) Specific cancer types: including thyroid cancer, sarcoma, and other malignant tumors with abnormal activation of the TRK signaling pathway.
2. Absolute taboo group
(1) Pregnant women: Animal studies have shown a risk of teratogenicity, and it is necessary to confirm the pregnancy status and take contraceptive measures before treatment.
(2) Severe allergy history: Prohibited for those who have experienced severe hypersensitivity reactions to drug ingredients.
(3) Combination therapy contraindications: Do not use in combination with strong CYP3A4 inducers as it may significantly reduce efficacy.
3. Caution should be exercised when using the target audience
(1) Liver dysfunction: Patients with moderate to severe damage need to reduce dosage, and Child Pugh C patients are not recommended to use it.
(2) Elderly patients aged 65 and above need to strengthen monitoring due to increased risk of concomitant medication and complications.
(3) Population during the reproductive period: Efficient contraceptive measures should be taken from the treatment period to 3 months after discontinuation of medication.
4. Special Restrictions
(1) Breastfeeding period: Medications may be secreted into breast milk, and it is recommended to suspend breastfeeding during treatment.
(2) Pediatric patients: Insufficient safety data for children under 12 years old, individualized assessment is needed.
(3) Surgical patients: Medication should be stopped for at least 2 weeks before surgery to prevent the risk of bleeding.
Disclaimer：《What are the target audiences for Voranigo, the Lusius version of Laos? Restrictions?》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！